Schering-Plough fertility drug succeeds in Phase III
This article was originally published in Scrip
Executive Summary
Schering-Plough's investigational single-injection fertility treatment corifollitropin alfa has met its primary endpoints in a Phase III non-inferiority trial comparing the drug with seven daily injections of recombinant follicle-stimulating hormone (FSH).